Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

Similar articles for PubMed (Select 23582674)

1.

Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study).

Macdonald K, Brié H, Vancayzeele S, Lee C, Bowles J, Piotrowski K, Hermans C, Abraham I.

Arch Cardiovasc Dis. 2013 Mar;106(3):124-34. doi: 10.1016/j.acvd.2012.11.006. Epub 2013 Mar 26.

2.

Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study).

Abraham I, MacDonald K, Song M, Ciesielski G, Pacheco C, Lee C, Cholette M, Kinsey K, Speaks P, Hermans C, Brié H, Reel S, Van der Niepen P, Yee B, Vancayzeele S.

Nutr Metab Cardiovasc Dis. 2013 Apr;23(4):314-22. doi: 10.1016/j.numecd.2011.06.005. Epub 2011 Sep 17.

PMID:
21930367
3.

Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study.

Lins R, Coen N, Aerts A, Macdonald K, Brié H, Hermans C, Shen YM, Lee C, Vancayzeele S, Mecum N, Abraham I.

Arch Cardiovasc Dis. 2011 Aug;104(8-9):428-34. doi: 10.1016/j.acvd.2010.12.005. Epub 2011 Feb 22.

4.

Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study).

Van der Niepen P, Woestenburg A, Brié H, Vancayzeele S, MacDonald K, Denhaerynck K, Lee C, Hermans C, Abraham I.

Ann Pharmacother. 2009 May;43(5):849-61. doi: 10.1345/aph.1L576. Epub 2009 Apr 7.

PMID:
19351876
5.

Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program.

Abraham I, MacDonald K, Hermans C, Aerts A, Lee C, Brié H, Vancayzeele S.

Vasc Health Risk Manag. 2011;7:209-35. doi: 10.2147/VHRM.S9434. Epub 2011 Mar 31. Review.

6.

Gender-specific, multi-level determinants of outcomes of antihypertensive treatment: a sub-analysis of the Belgian PREVIEW study.

MacDonald K, Lee CS, Chen HC, Ko ML, Fidel GE, Brié H, Hermans C, Vancayzeele S, Reel S, Van der Niepen P, Abraham I.

J Hum Hypertens. 2011 Jun;25(6):372-82. doi: 10.1038/jhh.2010.71. Epub 2010 Jul 15.

PMID:
20631740
7.

Effectiveness of amlodipine-valsartan single-pill combinations: hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the EXCELLENT study).

Lins R, Aerts A, Coen N, Hermans C, MacDonald K, Brié H, Lee C, Shen YM, Vancayzeele S, Mecum N, Abraham I.

Ann Pharmacother. 2011 Jun;45(6):727-39. doi: 10.1345/aph.1P663. Epub 2011 Jun 10.

PMID:
21666094
8.

Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.

Savoia C, Touyz RM, Endemann DH, Pu Q, Ko EA, De Ciuceis C, Schiffrin EL.

Hypertension. 2006 Aug;48(2):271-7. Epub 2006 Jun 19.

9.

Valsartan: more than a decade of experience.

Black HR, Bailey J, Zappe D, Samuel R.

Drugs. 2009;69(17):2393-414. doi: 10.2165/11319460-000000000-00000. Review.

PMID:
19911855
10.

Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.

Malacco E, Santonastaso M, Varì NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study.

Clin Ther. 2004 Jun;26(6):855-65. Erratum in: Clin Ther. 2004 Jul;26(7):1185. Clin Ther. 2005 Jan;27(1):142.

PMID:
15262456
11.

Hierarchical linear and logistic modeling of outcomes of antihypertensive treatment in elderly patients: findings from the PREVIEW study.

Abraham I, Demosthenes L, MacDonald K, Lee CS, Reel S, Brié H, Hermans C, Vancayzeele S, Van der Niepen P.

Arch Gerontol Geriatr. 2010 Jul-Aug;51(1):45-53. doi: 10.1016/j.archger.2009.07.009. Epub 2009 Aug 27.

PMID:
19716190
12.

A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.

Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R; COmparative Study of Efficacy of Irbesartan/HCTZ with Valsartan/HCTZ Using Home Blood Pressure Monitoring in the TreAtment of Mild-to-Moderate Hypertension (COSIMA) Investigators.

Am J Hypertens. 2005 Nov;18(11):1482-8.

PMID:
16280286
13.

Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control.

Zappe D, Papst CC, Ferber P; PROMPT Investigators.

Vasc Health Risk Manag. 2009;5:883-92. Epub 2009 Nov 2.

14.

Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.

Palatini P, Dorigatti F, Mugellini A, Spagnuolo V, Varì N, Ferrara R, Bertocchi F.

Clin Ther. 2004 Sep;26(9):1436-45.

PMID:
15531006
15.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group.

Lancet. 2004 Jun 19;363(9426):2022-31.

PMID:
15207952
16.

Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan.

Weycker D, Keskinaslan A, Levy DG, Edelsberg J, Kartashov A, Oster G.

Blood Press Suppl. 2008 Dec;2:5-12.

PMID:
19205091
17.
18.

Ambulatory hypertensive patients treated by cardiologists in France.

Blacher J, Peroz-Froz J, Huberman JP, Ferrini M, Jullien G, Guenoun M, Guedj-Meynier D.

Arch Cardiovasc Dis. 2013 Feb;106(2):86-92. doi: 10.1016/j.acvd.2012.11.002. Epub 2013 Jan 11.

19.

Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study.

Ohishi M, Takagi T, Ito N, Tatara Y, Hayashi N, Shiota A, Iwamoto Y, Katsuya T, Rakugi H, Ogihara T.

Hypertens Res. 2007 Dec;30(12):1187-92. doi: 10.1291/hypres.30.1187.

PMID:
18344623
20.

Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.

Andrés A, Morales E, Morales JM, Bosch I, Campo C, Ruilope LM; Valsartan in Renal Transplantation Group.

Transplant Proc. 2006 Oct;38(8):2419-23.

PMID:
17097955
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk